Why are prostaglandin analogs typically the first-line glaucoma medication?

Prostaglandin analogs provide the greatest IOP reduction of any single-agent topical drug class (25-35% from baseline), require only once-daily dosing (improving compliance), and have side effects that are primarily local (iris pigmentation, lash growth) rather than systemic. Beta-blockers were previously first-line but carry systemic risks (bradycardia, bronchospasm) that make prostaglandins preferable for most patients.

Why should timolol be used with caution in patients with asthma?

Timolol is a non-selective beta-blocker that blocks both beta-1 (cardiac) and beta-2 (bronchial) receptors. Beta-2 receptors in bronchial smooth muscle normally mediate bronchodilation. Blocking them causes bronchoconstriction, which can trigger severe bronchospasm in patients with asthma or COPD, even with topical administration because the drug is absorbed systemically through the nasolacrimal duct.

What is the mechanism by which prostaglandin analogs lower IOP?

Prostaglandin analogs lower IOP by increasing aqueous humor outflow through the uveoscleral (non-conventional) drainage pathway. They relax the ciliary muscle matrix and alter extracellular matrix components in the ciliary body, creating pathways for aqueous to flow out around the iris and through the ciliary body into the suprachoroidal space. They do not reduce aqueous humor production.

What systemic side effects can occur from topical eye drops?

Topical eye drops are absorbed systemically through the nasolacrimal drainage system (lacrimal sac and nasolacrimal duct lead to nasal mucosa, which has high vascular absorption). This bypasses hepatic first-pass metabolism, allowing relatively high drug concentrations to reach systemic circulation. Beta-blockers can cause bradycardia and bronchospasm. Alpha-2 agonists can cause hypotension and CNS depression. These risks can be minimized with nasolacrimal occlusion after instillation.

Glaucoma Medications: Mechanisms and Clinical Considerations

The Goal: Lowering IOP

The primary objective of glaucoma pharmacotherapy is to reduce intraocular pressure (IOP) to a target level that prevents further optic nerve damage. Since elevated IOP is the primary modifiable risk factor for glaucoma progression, all current first-line and adjunct therapies work through one of two physiological mechanisms:

Reducing the production of aqueous humor by the ciliary body.
Increasing the drainage of aqueous humor through the trabecular meshwork or the uveoscleral pathway.

Understanding which mechanism each drug class uses helps you predict their effects and anticipate their side effects.

Prostaglandin Analogs: First-Line Agents

Prostaglandin analogs are the most commonly prescribed first-line glaucoma medications in most clinical settings. Examples include latanoprost (Xalatan), bimatoprost (Lumigan), travoprost (Travatan Z), and tafluprost.

Mechanism: They increase aqueous outflow primarily through the uveoscleral pathway, a secondary drainage route around the conventional trabecular meshwork. They do not reduce aqueous production.

IOP reduction: Approximately 25-35% from baseline, making them the most potent single-agent glaucoma drops available.

Dosing: Once daily (typically at bedtime), which improves compliance compared to medications requiring multiple daily instillations.

Side effects to know for the CPO exam:

Iris pigmentation changes: Increased melanin production in iris melanocytes, which can permanently darken the iris color in patients with mixed-colored irides (e.g., green or hazel eyes). This is irreversible.
Periorbital skin darkening and increased pigmentation around the eye.
Hypertrichosis: Increased growth of eyelashes (longer, thicker, darker). This effect led to cosmetic use of bimatoprost as an eyelash growth agent (Latisse).
Cystoid macular edema (rare): More common in patients with prior intraocular surgery.
Uveitis activation (rare).

Warn patients using prostaglandins on only one eye that the treated eye may develop permanent iris color change over time. Bilateral treatment is preferable when both eyes need treatment, so both eyes change symmetrically.

Beta-Blockers: Long-Standing Adjunct Agents

Beta-adrenergic receptor blockers were the standard first-line glaucoma treatment for many years before prostaglandins became available. Examples include timolol (Timoptic), betaxolol (Betoptic), and levobunolol.

Mechanism: They reduce aqueous humor production by blocking beta-2 receptors on the ciliary body epithelium.

IOP reduction: 20-25% from baseline.

Systemic side effects are the primary concern because beta-blockers are absorbed systemically through the nasolacrimal duct:

Bradycardia: Slowing of the heart rate; dangerous in patients with heart block or sinus node dysfunction.
Bronchospasm: Contraindicated in patients with asthma or COPD.
Masking hypoglycemia symptoms in diabetic patients.
CNS effects: Depression, fatigue, and impotence have been reported.

Betaxolol is a cardioselective beta-1 blocker, theoretically less likely to cause bronchospasm than non-selective agents like timolol, but caution is still warranted in respiratory disease.

Eye drops can cause significant systemic effects because they are absorbed through the nasolacrimal duct directly into the bloodstream, bypassing hepatic first-pass metabolism. Always review the patient's medical history and medications before instilling glaucoma drops in the office.

Alpha-2 Agonists: Dual-Action Agents

Alpha-2 adrenergic agonists include brimonidine (Alphagan P) and apraclonidine.

Mechanism: They have a dual action: reducing aqueous humor production and increasing uveoscleral outflow. This combination gives them reasonable efficacy.

Side effects:

Allergic conjunctivitis: A significant proportion of patients (up to 25% with long-term use) develop ocular allergy, presenting with red, itchy eyes that worsen with continued use.
Dry mouth and nose.
CNS depression (drowsiness, fatigue): More significant in elderly patients.
Contraindicated in patients taking monoamine oxidase inhibitors (MAOIs).

Carbonic Anhydrase Inhibitors (CAIs)

Carbonic anhydrase inhibitors reduce aqueous humor production by inhibiting the carbonic anhydrase enzyme in the ciliary body, which is required for bicarbonate and fluid secretion into the posterior chamber.

Available forms:

Topical CAIs: Dorzolamide (Trusopt), brinzolamide (Azopt). Locally tolerable, with systemic effects generally minimal.
Oral CAIs: Acetazolamide (Diamox), methazolamide. Reserved for acute angle-closure glaucoma or when topical therapy is insufficient. Oral CAIs carry significant systemic side effects: paresthesias (tingling fingers), malaise, kidney stones, and dangerous sulfa allergies.

Topical CAIs are contraindicated in patients with known sulfa allergy, as the drug class is sulfonamide-derived.

Summary Comparison

Drug Class	Mechanism	Key Side Effects
Prostaglandin analogs	Increase uveoscleral outflow	Iris pigmentation, lash growth, skin darkening
Beta-blockers	Reduce aqueous production	Bradycardia, bronchospasm
Alpha-2 agonists	Reduce production + increase outflow	Allergy, dry mouth, drowsiness
Topical CAIs	Reduce aqueous production	Stinging, bitter taste, sulfa allergy

Key Takeaways

Glaucoma medications lower IOP by reducing aqueous production or increasing outflow (or both).
Prostaglandin analogs are first-line because of high efficacy (25-35% IOP reduction), once-daily dosing, and primarily local side effects.
Beta-blockers can cause bradycardia and bronchospasm through systemic absorption.
Alpha-2 agonists are dual-acting but cause frequent ocular allergy with long-term use.
Topical CAIs are sulfa-derived; avoid in patients with sulfa allergy.